This binding final civil judgment was issued in February 2027 by the United States District Court for the Northern District of Illinois, Case No. 1:26-cv-00482, involving mass manufacture and cross-border export of infringing disposable minimally invasive surgical forceps violating three U.S. medical device utility patents. The mainland Chinese manufacturing parent is anonymised as HuiDa Medical Instruments Co., Ltd., a Zhejiang factory specialising in laparoscopic surgical tool production, exporting infringing hardware to EU nations Germany, UK, Türkiye and India alongside the U.S. medical supply market. The patent plaintiff is U.S. medical tech firm SurgCore IP LLC, assignee of U.S. utility patents US 11,318,002, US 11,642,107 and US 11,978,331, covering ergonomic jaw clamping structures and anti-slip locking mechanisms for minimally invasive surgical instruments under 35 U.S.C. §101 et seq.
Starting March 2025, HuiDa Medical fully reverse-engineered the patented forceps core mechanical structures and locking assemblies without executing any formal patent licensing agreement or paying royalty fees, mass-machining infringing surgical instruments at its Zhejiang production base. To completely erase all traceable links between U.S.-bound medical cargo and the Chinese factory and evade treble damages under 35 U.S.C. §284, the group established a single-layer offshore separation vehicle: a wholly-owned Malaysia private limited trading shell named MedOcean Supply Sdn Bhd. Every U.S. customs entry declaration, Medline/Amazon Medical marketplace seller registration, ocean bill of lading, third-party medical payment merchant account and hospital distributor marketing listing exclusively used the Malaysia shell’s legal identity; HuiDa’s full Chinese corporate name was fully redacted and excluded from all cross-border commercial paperwork, a premeditated tactic to obstruct patent discovery and liability attribution to the mainland manufacturer.
Three core intentional concealment measures were deployed to mask the domestic infringing manufacturer:
1. Register MedOcean Supply Sdn Bhd under Malaysia SSM corporate rules that permit non-public disclosure of ultimate beneficial owners; all U.S. medical supply trade capital flowed through this Malaysia offshore entity, which falsely presented itself as an independent Southeast Asian importer with no manufacturing facilities in mainland China. No corporate registry record connected MedOcean to HuiDa Medical for 22 consecutive months of infringing medical device exports to the U.S.
2. Execute fake independent sourcing contracts falsely certifying MedOcean purchased all laparoscopic forceps hardware from unaffiliated Asian component vendors, while internal cloud ERP archives conclusively proved HuiDa held 100% equity of the Malaysia shell, controlled all medical-grade stainless steel raw material procurement, production batch scheduling and U.S. hospital distributor export sales strategy, and manufactured every infringing surgical unit in-house at its Zhejiang plant.
3. Route all U.S. medical distributor marketplace revenue to Malaysia offshore bank accounts before monthly profit wire transfers to HuiDa’s domestic Chinese corporate bank account, labelling all inbound offshore remittances as “medical machinery structural technical consulting service fees” to mischaracterise patented surgical hardware sales revenue as tax-exempt technical service income and obscure infringing profit streams from forensic accounting auditors and plaintiff patent counsel.
SurgCore IP Holdings first identified thousands of infringing disposable surgical forceps listings under MedOcean’s brand aliases on Medline’s wholesale portal and Amazon Business Medical in April 2025. Multiple formal cease-and-desist letters and patent infringement demand notices sent to MedOcean’s registered Malaysia address were ignored, and the offshore entity refused to disclose the actual Chinese manufacturing source of the infringing surgical equipment, forcing the patent owner to file federal patent litigation and initiate multi-jurisdictional discovery against Malaysia corporate records and mainland Chinese factory production data.
After the Illinois Northern district judge granted comprehensive cross-border discovery motions in October 2026, plaintiff counsel obtained full ERP server logs, Malaysia offshore bank transaction records, internal enterprise WeChat corporate chat archives and factory precision machining technical drawings, establishing multiple aggravated willful infringement factors distinct from prior portable energy storage, apparel and AI copyright/patent cases covered earlier: First, HuiDa’s in-house mechanical R&D team reverse-engineered SurgCore’s patented laparoscopic forceps jaw and locking assemblies, extracted the protected ergonomic clamping mechanism dimensional parameters, and only modified trivial handle plastic shell thickness values to create superficial technical differences while retaining 99.2% of the original novel inventive combination claimed in the three asserted utility patents. The court-appointed independent mechanical engineering forensic examiner confirmed literal infringement of 14 independent and dependent patent claims as defined under 35 U.S.C. §271, with trivial cosmetic handle adjustments incapable of negating direct manufacturing infringement liability for medical devices. Second, HuiDa’s senior R&D and factory management teams issued formal internal written standard operating protocols mandating full deletion of all reverse-engineering technical comparison files, U.S. medical device patent reference documents, and plaintiff cease-and-desist correspondence from factory cloud servers every 40 days. Recovered server access audit trails proved engineering staff permanently purged terabytes of critical patent-related technical records after receiving the plaintiff’s first infringement demand letter, constituting spoliation of evidence under Federal Rule of Civil Procedure 37, a separate sanctionable civil violation. Under binding Federal Circuit precedent in Halo Electronics v. Pulse Electronics, intentional destruction of material technical evidence creates a rebuttable legal presumption that the deleted records would have proven the defendant’s full advance knowledge of medical device patent infringement.
Third, the enterprise maintained uninterrupted mass production and U.S. ocean freight shipments of infringing laparoscopic forceps across nine sequential U.S. Customs IPR medical cargo seizures between May 2025 and November 2026, totalling 172,000 infringing disposable surgical instrument units with a combined legitimate wholesale value of over $5.8 million per U.S. Customs IPR medical device seizure valuation standards. After each border detention, the group simply registered new anonymous MedOcean wholesale sub-accounts and rerouted shipments through alternate East Coast U.S. ports to continue distributing infringing surgical hardware to American hospitals and medical supply distributors, demonstrating reckless disregard for U.S. federal medical device patent law and FDA import compliance rules.
The central legal dispute of the litigation centred on whether the Malaysia offshore trading shell operated as a mere alter ego of HuiDa Medical, allowing the federal court to pierce the corporate veil and impose full patent damages directly against the Chinese manufacturing parent, despite the complete exclusion of HuiDa’s name from all U.S.-facing medical supply commercial paperwork. The judge applied a multi-factor alter ego test under Illinois federal common law, ruling three decisive factors proved the offshore entity existed solely to conceal HuiDa’s infringing medical device manufacturing activity:
1. Complete lack of separate corporate formalities separating the two entities: all MedOcean offshore shell operating costs, medical steel raw material payments and executive salary disbursements were paid directly from HuiDa’s domestic Chinese bank accounts without intercompany loan documentation or formal board resolution votes; no separate independent office space, dedicated medical sales staff or standalone operational warehouse infrastructure existed for MedOcean Supply Sdn Bhd within Malaysia.
2. Total commingling of corporate assets: all U.S. medical wholesale sales revenue, offshore holding funds and domestic manufacturing capital were freely interchangeable across HuiDa and MedOcean with strict separation of corporate funds never maintained at any stage of the U.S. medical export operation.
3. The sole primary business purpose of the Malaysia offshore shell was to shield HuiDa from U.S. patent legal liability and FDA regulatory scrutiny, with no legitimate independent trading activity unrelated to exporting the infringing laparoscopic surgical forceps to American medical marketplaces.
The court issued a binding alter ego ruling in December 2026, holding HuiDa Medical Instruments Co., Ltd. jointly and severally liable for all patent damages alongside its wholly-owned Malaysia offshore shell subsidiary MedOcean Supply Sdn Bhd, rejecting all defendant arguments that the Malaysia firm operated as an independent unaffiliated medical trade intermediary with no ties to mainland Chinese surgical instrument manufacturing operations.
In the February 23, 2027 final written judgment, the Northern District of Illinois court issued sweeping punitive remedies grounded in 35 U.S.C. §284 treble damage provisions for willful utility patent infringement on medical devices, which permit enhanced damages up to three times the baseline compensatory award. Key binding holdings included:
1. Baseline compensatory damages of $3.82 million, elevated to a total treble damages award of **$11.46 million** against HuiDa Medical and MedOcean Supply Sdn Bhd, jointly and severally. The court applied the maximum 3x multiplier after weighing the enterprise’s single-layer Malaysia offshore concealment scheme, repeated disregard of cease-and-desist demands, intentional evidence spoliation, large-scale commercial profit motive from mass medical device patent infringement, and nine separate Customs medical cargo seizures without remedial compliance action.
2. Permanent nationwide U.S. medical device import exclusion injunction under 19 U.S.C. §1595a ordering U.S. Customs and Border Protection (CBP) to seize and forfeit all future laparoscopic surgical instrument shipments manufactured or supplied by HuiDa or its Malaysia offshore shell arriving at any American port of entry, with all detained infringing medical hardware subject to mandatory total destruction at the defendants’ sole financial cost.
3. Permanent nationwide medical wholesale marketplace takedown injunction mandating Medline, Amazon Business Medical and all other U.S. medical supply platforms to permanently disable every seller account registered under MedOcean’s trade aliases, freeze all associated platform payment wallet balances, and block future new account registrations linked to HuiDa’s corporate beneficial owners and executive management team.
4. Full reimbursement of the plaintiff’s complete attorney fees, mechanical engineering forensic appraisal costs, cross-border Malaysia corporate registry discovery administrative expenses and offshore bank record retrieval charges, totalling an additional $243,600 payable jointly by both corporate defendants pursuant to 35 U.S.C. §285 exceptional case fee-shifting rules.
5. Five-year corporate formation prohibition barring HuiDa’s controlling executives from registering any new Malaysia, Hong Kong, BVI or U.S.-based offshore medical trade entities for the purpose of importing surgical hardware and medical devices into the United States, to prevent repeated offshore concealment tactics in future cross-border medical equipment export commerce.
The court explicitly emphasised in its judgment that the deliberate full redaction of the Chinese medical device manufacturer’s legal identity from all U.S.-bound shipping, customs and medical marketplace documents constituted an independent aggravating factor justifying maximum treble damage enhancement, as the Malaysia offshore structure was constructed entirely to obstruct patent holders’ ability to identify, pursue and remedy large-scale intentional utility patent infringement originating from mainland Chinese medical production facilities.
This landmark Northern District of Illinois judgment established critical enforceable compliance standards for all Chinese cross-border medical hardware and surgical instrument manufacturers exporting patented medical technology products to the United States: First, offshore Malaysia, Hong Kong, BVI or Singapore holding/trade subsidiary structures cannot be utilised to intentionally redact or erase the domestic manufacturing parent’s full legal identity from U.S. customs, shipping and medical marketplace filings to evade U.S. patent and FDA liability; federal courts will readily pierce alter ego corporate veils where offshore entities exist solely as liability-shielding front operations for mainland infringing medical factories. Second, systematic concealment of manufacturing source identities, spoliation of patent-related technical digital evidence and repeated disregard of formal patent cease-and-desist notices will trigger maximum treble damages under Title 35 U.S.C., far exceeding ordinary innocent infringement financial penalties for medical device products subject to strict FDA oversight. Third, full transparency of domestic corporate ownership, manufacturing origins and complete medical supply chain documentation must be maintained on all cross-border export paperwork destined for the United States; deliberate misrepresentation of entity identity to U.S. federal agencies, CBP and medical e-commerce platforms creates a rebuttable legal presumption of willful patent infringement under §284(c) of the U.S. Patent Act.For Chinese enterprises exporting patented surgical and diagnostic medical hardware to EU nations Germany, UK, Türkiye and India alongside the U.S., parallel intellectual property risk exposure applies under regional EU medical device patent directives; anonymous offshore shell concealment schemes carry equivalent heightened damage awards in European national IP courts and EUIPO opposition proceedings for regulated medical products.
1. https://www.uspto.gov/patents/laws-and-statutes USPTO Official Full Text of Title 35 U.S. Code (U.S. Patent Act)
2. https://www.cbp.gov/trade/ipr U.S. Customs and Border Protection Official Intellectual Property Rights Enforcement Portal
3. https://pacer.uscourts.gov PACER Federal Court Electronic Records System (Public civil patent judgment access for U.S. district court cases)
4. https://www.wipo.int/patents/en/ WIPO Global Patent Treaty & Cross-Border Medical Device IP Enforcement Guidance
